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AbstrAct
Introduction Endobronchial valve placement has potential 
as a treatment for patients with chronic obstructive 
pulmonary disease (COPD). However, a robust evidence 
base will be needed to convince commissioners of 
healthcare that it is a high-value treatment. We sought to 
develop the evidence base by performing an individual 
patient-level analysis of randomised controlled trials in 
people with heterogeneous emphysema and an absence of 
collateral ventilation.
Methods A literature search (PROSPERO register 
CRD42016048127) identified two trials meeting 
these criteria, the BelieVeR-HIFi and STELVIO studies. 
Anonymised individual patient data were obtained from 
investigators and analysed. The primary outcome measure 
was a comparison of change in forced expiratory volume in 
1 s (FEV1) from baseline between the treatment and control 
groups. Secondary end points were change from baseline 
in 6 min walk distance (6MWD), Medical Research Council 
dyspnoea score and St George’s Respiratory Questionnaire 
(SGRQ).
results 114 individuals were treated with 3-month to 
6-month follow-up data available for 101 individuals. 
FEV1 improved by 23.1 (±28.3)% in patients treated 
with valves with a mean (95% CI) difference in response 
between groups of 17.8 (26.5, 9.2)% (p<0.0001). Relative 
to controls valve placement was associated with a fall in 
residual volume of 0.64 (0.43, 0.86) L (p<0.0001), a 9.5 
(3.5, 15.6) unit fall in SGRQ (p=0.0022) and a 64.2 (94.0, 
34.5) m increase in 6MWD. There were three deaths in the 
treatment arm and the pneumothorax rate was 15%.
conclusions These data strengthen the evidence that 
endobronchial valve treatment can produce clinically 
meaningful improvements in appropriately selected COPD 
patients.
bAckground
Chronic obstructive pulmonary disease 
(COPD) is characterised by the presence 
of bronchitis and emphysema. The latter 
process, due to breakdown of elastic alve-
olar tissue, leads to increased lung compli-
ance and gas trapping. Lung hyperinflation 
worsens with exercise leading to breath-
lessness and is associated with reduced 
physical activity1 2 and reduced survival.3 
Inhaled bronchodilator medications have 
only modest impacts on symptoms and do 
not alter the natural history of the disease. 
In selected patients with a heterogeneous 
pattern of emphysema, surgical resection 
can be targeted at the worst affected areas of 
lung tissue which contribute disproportion-
ately to gas trapping and hyperinflation, and 
so improve respiratory mechanics.4 5 Lung 
volume reduction surgery (LVRS) improves 
symptoms and prolongs survival6–8 but can 
be associated with significant morbidity and a 
risk of death, with a cost per quality adjusted 
life year (QALY) of at least $40 000.9 
A more recent approach has been to 
instead use endobronchial valves to occlude 
the airways supplying the worst affected part 
of the lung.10–13 This is intended to cause atel-
ectasis in the target lobe, with a similar impact 
on the function of the rest of the lung as seen 
in LVRS. However, atelectasis will only occur 
in the absence of significant collateral ventila-
tion between the target lobe and the adjacent 
one. Because of this, the success rate of valve 
placement in early studies was low, impacting 
on the value of endobronchial valves as a 
therapeutic intervention.13–15 Collateral venti-
lation can now be measured directly using the 
Chartis pressure/flow catheter system.16–18
To cite: Klooster K, 
Slebos D-J, Zoumot Z, et al. 
Endobronchial valves for 
emphysema: an individual 
patient-level reanalysis 
of randomised controlled 
trials. BMJ Open Resp Res 
2017;4:e000214. doi:10.1136/
bmjresp-2017-000214
Received 15 May 2017
Revised 10 October 2017
Accepted 11 October 2017
1Department of Pulmonary 
Diseases, University of 
Groningen, University Medical 
Center Groningen, Groningen, 
The Netherlands
2Respiratory and Critical Care 
Institute, Cleveland Clinic Abu 
Dhabi, Abu Dhabi, United Arab 
Emirates
3NIHR Respiratory Biomedical 
Research Unit, Royal 
Brompton and Harefield NHS 
Foundation Trust and Imperial 
College, London, UK
Correspondence to
Dr Nicholas S Hopkinson;  
 n. hopkinson@ ic. ac. uk
Endobronchial valves for emphysema: 
an individual patient-level reanalysis of 
randomised controlled trials
Karin Klooster,1 Dirk-Jan Slebos,1 Zaid Zoumot,2 Claire Davey,3 Pallav L Shah,3 
Nicholas S Hopkinson3
Chronic obstructive pulmonary disease
Key messages
 ► Can endobronchial valve placement improve health 
outcomes in selected patients with heterogeneous 
emphysema and an absence of collateral ventilation
 ► Endobronchial valves improve lung function, 
exercise capacity and health status at 3–6 months 
after the procedure
 ► Combining patient-level data from randomised 
controlled trials of bronchoscopic lung volume 
reduction with endobronchial valves strengthens 
the evidence that this therapy can improve lung 
function, exercise capacity and quality of life in 
appropriately selected patients with heterogeneous 
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Table 1 Baseline characteristics
All n=114 Control n=59 Treatment n=55 P value (t-test)
Age (years)  60.2 (8.6)  60.7 (8.1)  59.7 (9.1) 0.5
Per cent female  55  66  44 0.016
BMI (kg/m2)  24.4 (4.2)  24.3 (4.1)  24.4 (4.3) 0.90
mMRC   2.7 (0.6)   2.7 (0.56)   2.7 (0.70) 0.74
Smoking (pack/years)  43.5 (23.3)  42.2 (22.6)  44.7 (24.1) 0.56
SGRQ symptoms  59.4 (20.0)  61.2 (20.7)  57.5 (19.2) 0.32
SGRQ activity  85.7 (10.9)  87.2 (9.8)  84.0 (11.8) 0.12
SGRQ impacts  50.7 (17.3)  51.3 (17.2)  50.0 (17.7) 0.68
SGRQ total  63.0 (13.5)  64.1 (13.2)  61.8 (13.9) 0.36
FEV1 (L)   0.86 (.30)   0.82 (0.28)   0.90 (0.32) 0.14
FEV1 %pred  30.6 (8.8)  30.5 (8.9)  30.6 (8.9) 0.95
TLC %pred 133.6 (13.2) 137.0 (13.1) 130.0 (12.5) 0.004
RV %pred 222.5 (37.9) 230.5 (39.2) 213.8 (34.8) 0.018
RV/TLC  60.7 (8.4)  62.4 (8.1)  58.8 (8.5) 0.026
FRC %pred 188.5 (29.7) 198.5 (29.3) 176.5 (26.2) 0.011
Tlco %pred  37.7 (9.8)  37.2 (9.8)  38.1 (9.8) 0.65
PaCO2 kPa   9.4 (1.3)   5.0 (0.6)   5.0 (0.9) 0.66
PaO2 kPa   9.4 (1.3)   9.3 (1.1)   9.4 (1.5) 0.52
6 min walk distance (m) 360 (87) 359 (85) 361 (89) 0.89
BODE score   5.9 (1.3)   5.9 (1.2)   5.9 (1.4) 0.87
BMI, body mass index; BODE, BMI, obstruction, dyspnoea, exercise capacity; FEV1, forced expiratory volume in 1 s; FRC, functional residual 
capacity; mMRC, modified Medical Research Council dyspnoea score; PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension; 
RV, residual volume; SGRQ, St George’s Respiratory Questionnaire; TLC, total lung capacity.
Case series and single-centre trials have demonstrated 
that endobronchial valve treatment in patients with 
emphysema can lead to improvements in symptoms, lung 
function and exercise capacity,11–13 reductions in dynamic 
hyperinflation19 and improvements in oxygen kinetics20 
and chest wall synchrony.21 Moreover, where target lobe 
volume loss is seen on CT, a substantial survival benefit 
has been observed compared with those where valve 
treatment has been ineffective.14 15
We wished to combine data from existing single-centre 
studies to address the question ‘in patients with emphy-
sema and a target lobe with proven absence of interlobar 
collateral ventilation, what is the effect of endobronchial 
valves placed to achieve lobar occlusion, on lung func-
tion, exercise capacity and health status?’
Methods
The study was registered on the PROSPERO Inter-
national prospective register of systematic reviews 
CRD42016048127. We searched PubMed using the 
terms ‘endobronchial valves (AND) emphysema’ on 22 
September 2016. This identified 116 abstracts. Twelve 
of these were clinical trials. Review of the abstracts 
identified two trials where patients with emphysema 
were randomised to endobronchial valve placement 
or standard care with identification of the presence of 
interlobar collateral ventilation using the Chartis system 
(Pulmonx).11 12 Complete, anonymised, individual 
patient data were obtained from the investigators for 
analysis.
Data were checked for: missing items, internal data 
consistency and randomisation integrity. Summary tables 
were checked with the trial protocol and latest trial report 
or publication.
The primary outcome measure was a comparison 
of change in forced expiratory volume in 1 s (FEV1) 
between the endobronchial valve treatment and control 
groups. Secondary end points were change from baseline 
to 3 months (BeLieVeR-HIFi) or to 6 months (STELVIO) 
in 6 min walk distance (6MWD), Medical Research 
Council (MRC) dyspnoea score and St George’s Respi-
ratory Questionnaire (SGRQ). The different time points 
in the two trials were merged as a measure of the effec-
tiveness of the intervention because the impactof the 
intervention was expected to be much greater than spon-
taneous decline over a short period of time. Statistical 
analysis was carried out using StatView 5. Changes were 
compared between treatment and control groups using 
unpaired t-tests. Analysis of covariance using baseline 
values as a covariate together with treatment allocation 
and which study individuals were in was used to establish 
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Figure 1 Percentage change in forced expiratory 
volume in 1 s (FEV1) in patients treated with endobronchial 
valves and control subjects. Boxes represent 25th–75th 
percentiles, bars 10th–90th percentiles (P<0.0001).
Table 2 Response to treatment
Control, n=57 Endobronchial valves, n=44 Between-group difference (95% CI) t-test
Δ FEV1 (mL) 40 (17) 185 (70) 150 (60 to 230) 0.0006
Δ FEV1 (%) 5.3 (14.7) 23.1 (28.3) 17.8 (26.5 to 9.2) <0.0001
Δ SGRQ symptoms −5.9 (15.2) −4.7 (22.8) 1.2 (8.7 to 6.4) 0.76
Δ SGRQ activity −0.3 (10.8) −14.7 (20.9) −14.4 (−8.0 to 20.7) <0.0001
Δ SGRQ impacts −3.7 (13.2) −14.2 (22.2) −10.4 (−3.3 to 17.5) 0.004
Δ SGRQ total −3.2 (9.8) −12.7 (20.0) −9.5 (−3.5 to 15.6) 0.0022
Δ TLC (L) 0.02 (0.6) −0.45 (0.47) −0.47 (−0.22 to 0.73) 0.0004
Δ RV (L) −0.06 (0.36) −0.70 (0.52) −0.64 (−0.425 to 0.863) <0.0001
Δ RV/TLC (%) −0.7 (3.4) −5.95 (7.3) −5.2 (−3.0 to 7.4) <0.0001
Δ FRC (L) 0.82 (0.48) −0.53 (0.66) −0.61 (−0.38 to 0.83) <0.0001
Δ Tlco(%predicted) 0.02 (12.8) 5.80 (14.6) 5.7 (11.6 to 0.03) 0.051
Δ PaCO2 (kPa) −0.01 (0.43) −0.14 (0.59) −0.13 (0.07 to 0.34) 0.02
Δ PaO2 (kPa) 0.21 (0.97) −0.29 (1.1) −0.50 (0.07 to 0.93) 0.03
Δ 6MWD (m) −5.6 (61.1) 58.6 (87.2) 64.2 (94.0 to 34.5) <0.0001
6MWD, 6min walk distance; FEV1, forced expiratory volume in 1 s; FRC, functional residual capacity; PaCO2, arterial carbon 
dioxide tension; PaO2, arterial oxygen tension; RV, residual volume; SGRQ, St George’s Respiratory Questionnaire; Tlco, 
carbon monoxide transfer factor.
Figure 2 Change in residual volume (RV) in patients 
treated with endobronchial valves and control subjects. 
Boxes represent 25th–75th percentiles, bars 10th–90th 
percentiles (P<0.0001).
(CV)-positive patients (n=4) treated in the BeLieV-
eR-HIFi were excluded.
No ethical approval for this reanalysis of anonymised 
data was obtained.
results
Literature search identified two studies. The UK-based 
BeLieVeR-HIFi trial (ISRCTN04761234) was a 
double-blind study which randomised 50 patients on 
a one-to-one basis to endobronchial valve placement, 
intended to achieve lobar occlusion11 or to bronchos-
copy with a sham-bronchoscopy procedure. Patients 
were selected on the basis of hyperinflation, hetero-
geneous emphysema and interlobar fissure adjacent 
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Figure 3 Change in 6 min walk distance (6MWD) in 
patients treated with endobronchial valves and control 
subjects. Boxes represent 25th–75th percentiles, bars 
10th–90th percentiles (P<0.0001).
Figure 4 Change in St George’s Respiratory Questionnaire 
(SGRQc) in patients treated with endobronchial valves and 
control subjects. Boxes represent 25th–75th percentiles, 
bars 10th–90th percentiles (P=0.0022).
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  Respiratory failure 2 0
  COPD with cor pulmonale 1 0
COPD, chronic obstructive pulmonary disease.
intact. Allocation was by predetermined block rando-
misation, obtained by telephone link from the bron-
choscopy suite after the patient had been sedated. 
Collateral ventilation was measured but patients were 
treated even if CV positive (n=4). For the purpose 
of the present analysis, the CV-positive patients were 
excluded, as they fall outside the hypothesis being 
addressed. Outcome measures were assessed at 3 
months post procedure by investigators blind to study 
allocation. There were two deaths in the treatment 
arm, one because of complications of a valve removal 
procedure and one from cor pulmonale. One control 
patient was too unwell to attend for follow-up, so 
follow-up data were available for 24 control patients 
and 19 treated patients.
A second Dutch study (STELVIO trial—Netherlands 
Trial Register number, NTR2876) randomised 68 
hyperinflated COPD patients, with a target lobe based 
on visual inspection of the CT, on a one-to-one basis to 
endobronchial valve placement or usual care.12 Alloca-
tion was performed using a randomisation list that had 
been computer-generated in blocks of four. The gener-
ated codes were placed in opaque-sealed envelopes, 
which were numbered sequentially. The assigned enve-
lope was opened before bronchoscopy in the presence 
of the patient and bronchoscopist. Bronchoscopy was 
then performed. Eighty-four patients entered the study, 
but patients with collateral ventilation (n=13) or airways 
unsuitable for endobronchial valve placement (n=3) 
were excluded. Pulmonary function tests were assessed 
6 months following the procedure by blinded assessors. 
One control patient withdrew. One treated patient 
died due to end-stage COPD with respiratory failure 
58 days after treatment and one was withdrawn from 
the study by the investigators because of a prolonged 
admission to the critical care unit due to COPD exac-
erbation caused by a viral infection. Seven patients 
discontinued the study because their valves had been 
removed—two at patient request because of perceived 
lack of efficacy, two because of bronchial torsion, two 
because of recurrent pneumothorax and one because 
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study were therefore available for 25 treated patients 
and 33 controls.
The BeLieVeR-HIFi trial was funded by the Efficacy 
and Mechanism Evaluation Programme, funded by the 
MRC and managed by the National Institute for Health 
Research (NIHR) on behalf of the MRC-NIHR partner-
ship (EME 10/90/10). The valves used in the trial were 
provided free of charge by the device company, Pulmonx. 
The STELVIO trial was supported by a grant (171101008, 
to the University Medical Centre Groningen) from the 
Netherlands Organisation for Health Research and 
Development (ZonMw) and by innovation funding from 
the University Medical Centre Groningen. Valves were 
obtained commercially from Pulmonx (all catheters at 
regular market prices and all valves at 50% of the market 
list price).
Baseline data for 114 patients were available, 55% 
female, aged mean (SD) 60.2 (8.6) years, with a mean 
(SD) FEV1 30.6 (8.9)% predicted, with follow-up data 
available for 101 (treatment n=44 and control n=57). The 
groups were well matched for spirometry, gas transfer, 
symptoms, exercise capacity and BODE (BMI, obstruc-
tion, dyspnoea, exercise capacity) score, but the control 
group were more hyperinflated (table 1).
FEV1 improved by 23.1 (±28.3)% in patients treated 
with valves with a mean (95% CI) difference in response 
between groups of 17.8 (26.5, 9.2)% (P<0.0001) (figure 1, 
table 2). Valve placement was associated with statistically 
and clinically significant improvements in lung volumes 
(figure 2), exercise capacity (figure 3) and quality of life 
(figure 4). Outcomes did not differ significantly between 
the two trials for change in FEV1, residual volume 6MWD 
or SGRQ (P=0.79, 0.28, 0.16 and 0.21, respectively) 
although MRC dyspnoea score improved to a greater 
extent in the STELVIO study (P=0.002)
Adverse events are described in table 3. There were a 
total of eight pneumothoraces in the treatment arm and 
one in a control subject during the follow-up period.
dIscussIon
The present data combine results from two randomised 
controlled trials which evaluated the impact of endo-
bronchial valve placement to achieve lobar occlusion in 
patients with heterogeneous emphysema, where collat-
eral ventilation had been excluded using the Chartis 
catheter system.11 12 They further strengthen the evidence 
that endobronchial valve treatment can, in appropriately 
selected patients, produce clinically meaningful improve-
ments in lung function, exercise capacity and health 
status. The amplitudes of changes exceeded convention-
ally defined minimum clinically important differences 
(MCID)—a 15% increase for FEV1, 350 mL reduction 
for the residual volume,22 an increase of 26 m for the 
6MWD23 and a 4-point decrease in the SGRQc.24 25 It also 
exceeds the more recently proposedMCID of 7 SGRQ 
points at 6 months for bronchoscopic interventions in 
advanced COPD.26
Methodological issues
We combined data from two studies which were similar 
in that they randomised patients with severe emphysema 
and a suitable target lobe to endobronchial valve place-
ment or usual care. The trials were well conducted with 
study methodology including allocation and blinding 
clearly described with a low risk of bias. There were a 
number of differences between the studies, though we do 
not feel that they preclude combining the data as we have 
done. Follow-up was at 3 months in the BeLieVeR-HIFi 
study11 and 6 months in STELVIO,12 but the size of the 
response observed is significantly larger than the likely 
spontaneous decline over that time period. The former 
study included a control bronchoscopy, so participants 
were blind to treatment allocation whereas treatment 
was open label in STELVIO. This might have influenced 
response to questionnaires or exercise tests which are 
effort dependent, but in fact, improvements in these 
with treatment were similar between studies. Of note, 
the improvement in SGRQ score exceeded the 8-point 
threshold used in the National Emphysema Treatment 
Trial to allow for the lack of blinding in that study.6
hazards of therapy
Our study extends the data available on harms associated 
with endobronchial valve placement. Acute exacerba-
tion-like events are common in the early period after valve 
placemen. Pneumothorax remains a significant concern, 
occurring in 15% of individuals treated. Pneumotho-
races occur because the valve placement has been effec-
tive, causing a change in the conformation of the lung 
which leads to tearing and air leakage. For this reason, 
pneumothorax was unusual in early trials,13 but the rate 
has increased as selection criteria for trials have become 
more precise.11 12 27 Most of these episodes respond to 
conventional treatment with an intercostal drain but 
they can be fatal, especially in a group of patients who 
already have significant ventilatory limitation. It is there-
fore recommended that patients should be observed for 
several days as an inpatient following the procedure.
conclusIon
This analysis provides further evidence for the efficacy of 
endobronchial valves as a therapeutic option in COPD 
patients with advanced emphysema. Longer-term data are 
becoming available suggesting that benefits, including 
survival benefits,14 of valve treatment are sustained and 
suggest that this may be a relatively high-value therapy 
in COPD,28 with a cost per QALY of approximately 
€25 000.29 Good outcomes from lung volume procedures 
will depend on a multidisciplinary approach and the 
development of effective referral pathways.7 8 28 30 Further 
work is needed to establish the relative long-term benefits 
of valve placement and LVRS. TheComparative Effective-
ness of Lung volume reduction surgery for eEphysema 
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now underway to address this http://www. isrctn. com/ 
ISRCTN19684749
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